Fujifilm Announces Appointment Of FUJIFILM Sonosite’s Rich Fabian To Board Of AdvaMed

FUJIFILM Sonosite, Inc., the world leader in point-of-care ultrasound, has announced Rich Fabian, the company’s President, and Chief Operating Officer, was appointed to the board of The Advanced Medical Technology Association (AdvaMed), a Washington D.C.-based trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world.

“I am proud to be a member of the AdvaMed board, particularly now. Since the very onset of the coronavirus (COVID-19), AdvaMed members have been on the front lines, providing patients and health care providers with the protective equipment, diagnostic tests, ventilators and other vital medical devices and supplies needed to defeat this pandemic,” said Rich Fabian, President and Chief Operating Officer, FUJIFILM Sonosite, Inc. “At Sonosite, we’ve stepped up to provide educational resources on our point-of-care ultrasound systems, which have been critical to the care delivery of COVID-19 patients. Similarly, AdvaMed steps up in times of crisis and has been a steady advocate for our industry, facilitating advances in medical technologies in the form of new diagnostics, new treatments, and new medical devices.”

As leaders in point-of-care ultrasound (POCUS), Fujifilm is dedicated to empowering clinicians, affording them the ability to bring ultrasound to any patient, anywhere, at any time. The company pushes the boundaries of innovation with a progressive product line, educational programs, and advocacy for a broader understanding of the benefit of POCUS.

AdvaMed advocates globally for the highest ethical standards and patient access to safe, effective, and innovative medical technologies that save and improve lives. Member companies of AdvaMed produce the medical devices, diagnostic products and health information systems that are transforming global health care through earlier disease detection, less invasive procedures, and more effective treatments.

“We’re excited to have Rich join the AdvaMed Board of Directors.  He is widely recognized as a strong advocate for the MedTech Industry- especially the promotion of breakthrough technologies and innovative solutions for our most pressing health needs,” says Scott Whitaker, President, and CEO of AdvaMed. “We look forward to his contributions as a board member, especially during these challenging times as our industry is working to deliver the devices and diagnostics crucial to our fight against COVID-19.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.